ONO PHARMACEUTICAL CO.,LTD.

September 13, 2017

Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress

Boulder, Colo., (September 9, 2017) – Array BioPharma (Nasdaq: ARRY) and Pierre Fabre announced results from Part 2 of the Phase 3 COLUMBUS study evaluating binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The primary analysis of Part 2 compared progression free survival (PFS) in patients treated with binimetinib 45 mg twice daily plus encorafenib 300 mg daily (COMBO300) to patients treated with encorafenib 300 mg daily as a single agent. Part 2 of the study was designed specifically to measure the contribution of binimetinib to the combination by holding the dose of encorafenib at 300 mg in both arms.

Ono Pharmaceutical Co., Ltd. (“ONO”) entered into the license agreement with Array BioPharma Inc. regarding binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor in May 2017 and received rights to develop and commercialize both products in Japan and South Korea.

Binimetinib and encorafenib are currently in two global Phase 3 clinical trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study including Japan and South Korea) and BRAF-mutant colorectal cancer (BEACON CRC study including South Korea) as a combination therapy.

Please click here for the press release distributed by Array BioPharma Inc.

ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
Public_relations@ono.co.jp